Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Amazon Great Indian Festival 2020 - Electronics
Stock Report

| More

HCG - Strand Life Sciences Launch StrandAdvantage500 to Broaden Patient Access to Genomic Testing

Posted On: 2020-09-23 04:39:57


Envisioned to drive a new standard of cancer care, HealthCare Global Enterprises Limited (HCG Cancer Hospital Bengaluru) and Strand Life Sciences launched comprehensive genomic profiling (CGP), an approach to detect multiple actionable cancer biomarkers at 'one go' to optimize treatment for better clinical outcomes. HCG has joined hands with Strand to develop StrandAdvantage500, a simple and comprehensive Next Generation Sequencing (NGS) based assay that analyses cancer-relevant genetic alterations from DNA and RNA derived from a patient's tumor in one integrated workflow.

Speaking about the launch, Dr. B.S. Ajaikumar, Chairman and CEO, HCG Enterprises Ltd., said, "Cancer cases in India are on the rise, and the goal is to offer affordable as well as right cancer care. We have witnessed instances where patients do not respond to certain drugs due to their heterogeneous genetic makeup. Partnering with Strand and Illumina, we have been diligently profiling our patients to understand their genomic makeup and manage them accordingly. However, with CGP based tumor profiling, we will have consolidated cancer-relevant biomarker detection to understand more actionable genetic alterations upfront. With the launch of CGP using Strand Advantage500, HCG aims to implement an individualized predictive treatment model that will revolutionize cancer treatment by making it accessible for patients by offering substantial saving to the healthcare system. It will focus on improved outcomes, and ultimately follow the HCG way of treating cancer: the right way, the first time."

Dr Ramesh Hariharan, CEO, Strand Life Sciences, said, "As preferred partner of global diagnostic network, our goal is to be committed in helping the clinicians to make the right clinical decision for their patients. With cutting-edge Genomics and Bioinformatics expertise, strong multidisciplinary team and R&D capabilities, the launch of CGP using StrandAdvantage500 will immensely help to understand the heterogeneous disease like cancer."

Dr. Mithua Ghosh, Director and Head, Clinical Diagnostics, said, "Understanding the genetic profile of cancer helps oncologists penetrate the root cause of the disease at molecular and genetic level. StrandAdvantage500 enables simultaneous detection of multiple oncology biomarkers associated with approved and developing therapies across multiple cancer types and other genetic signatures such as tumor mutational burden (TMB) and microsatellite instability (MSI), which are the emerging biomarkers of immunotherapy. In a series of studies done in our laboratory, it was observed the up to 70-80% of patients had actionable genetic alterations identified by CGP. This information will enable the oncologists to use more targeted and immunotherapy for their patients and lead to more clinical trial enrollment."

Comprehensive genomic profiling with StrandAdvantage500 will overcome the challenge of iterative testing with limited biopsy samples and enable us to consolidate the detection of biomarkers into a single assay, thus saving precious biopsy samples, reducing the need of rebiopsy and provides faster and comprehensive results. This innovative approach will help in managing the disease better and design treatment with best possible clinical outcomes.

Shares of HealthCare Global Enterprises Ltd was last trading in BSE at Rs.121.1 as compared to the previous close of Rs. 119.8. The total number of shares traded during the day was 1754 in over 111 trades.

The stock hit an intraday high of Rs. 121.55 and intraday low of 119.35. The net turnover during the day was Rs. 212171.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com

Amazon Great Indian Festival 2020 - Mobiles





Other Headlines:

Zydus Cadila receives tentative approval from USFDA for Linagliptin Tablets

Lakshmi Electrical Control Systems Ltd Q2 PAT up QoQ at Rs. 0.62 crore

HAL and Tech Mahindra Sign Us 400 Crore Contract for 'Project Parivartan'

BASF India Ltd gets stay on recovery of Demand Notice pertaining to FY 2011-12 received from the Commercial Tax Department, Karnataka

Equity Shares of Khaitan Chemicals & Fertilizers Limited to list in NSE

Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India

UTI Asset Management Company Consolidated net profit for the Quarter ended September 30, 2020 is Rs. 119 Crore

L&T Construction bags contract to build India's first High-Speed Rail Corridor

Thyrocare Technologies Ltd Board declares interim dividend of Rs. 10

Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals

Pidilite acquires Consumer & Bazaar business of Araldite in Indian Sub-Continent

Indiabulls Housing Finance Ltd. raises Rs. 20 Crores by selling part of its stake in Oaknorth Holdings Ltd

UTI Asset Management Company Ltd Board recommends Final Dividend of Rs. 7

Moody's withdraws ratings of ICICI Bank's Bahrain Branch for business reasons

CAMS board to consider Q2FY21 results, interim dividend on Nov 11, 2020

Pioneer Embroideries Ltd board to approve preferential issue, Q2 results on Nov 7, 2020

Thyrocare Technologies Ltd reports Rs. 43.05 crore consolidated PAT in Q2FY21

Hero MotoCorp Ltd reports consolidated PAT of Rs. 958.49 crore in Q2FY21

Orient Electric Ltd Q2 net profit up at Rs. 32.42 crore

CG Power and Industrial Solutions Ltd posts consolidated profit in Q2FY21 due to exceptional items

Texmo Pipes & Products Ltd allots 28,75,000 shares at Rs. 13.90

Sharda Cropchem Ltd board declares interim dividend of Rs. 2 for FY21

Texmo Pipes & Products Ltd posts PAT of Rs. 1.72 crore in Q2

MCX's consolidated PAT at Rs. 58.55 crore in Q2 FY2020-21

Navin Fluorine International Ltd board declares interim dividend of Rs. 5 for FY21

Ajanta Pharma Ltd Board to consider Buy-back of equity shares

Wipro to acquire Encore Theme Technologies Private Limited, a specialist Finastra software partner in financial services

Blue Star's consolidated revenue for Q2FY21 at Rs 902.12 crores; net profit at Rs 15.32 crores

PI Industries Ltd Q2FY21 consolidated net profit jumps to Rs. 217.6 crore

Cummins India Ltd Q2FY21 consolidated net profit at Rs. 173.16 crore

Sharda Cropchem Ltd Q2FY21 consolidated PAT at Rs. 19.03 crore

Larsen & Toubro Ltd board approves special dividend of Rs. 18

Infosys Completes acquisition of Blue Acorn iCi

Mohit Talwar completes tenure as Max Group Vice Chairman

BEL pays Rs 174.44 Crore Final Dividend to Govt of India

CRISIL upgrades long-term rating of Aarti Drugs Ltd

HSIL Ltd posts surge in PAT to Rs. 36.47 crore in Q2FY21

L&T Q2 consolidated net profit soars to Rs. 5520.27 crore

AU Small Finance Bank Ltd Q2 net profit jumps to Rs. 321.87 crore

AXIS Bank Ltd posts consolidated PAT of Rs. 1849.05 crore in Q2FY21

Navin Fluorine International Ltd posts consolidated PAT of Rs. 64.42 crore in Q2FY21

ICICI Securities Ltd board recommends interim dividend of Rs. 8

Cipla launches 'ELIFast' (IgG ELISA test) for COVID-19 antibody detection

TCS Named a Leader and Star Performer in Finance & Accounting Services by Everest Group

Yasho Industries Ltd migrates from BSE SME to Bombay Stock Exchange Mainboard

Infosys turns carbon neutral 30 years ahead of 2050, the timeline set by the Paris Agreement

GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended September 30, 2020

Schaeffler India Limited announces Q3 results for the period ended September 30, 2020

NBCC Ltd signs MoU with DTC

APL Apollo Tubes Ltd Board approves sub-division of Equity Shares







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019